Vorinostat (SAHA) in Uterine Sarcoma

Inclusion Criteria: * Histologically confirmed metastatic uterine sarcoma (endometrial stromal sarcoma, undifferentiated uterine sarcoma, leiomyosarcoma, adenosarcoma and carcinosarcoma * High HDAC-positivity of the tumor determined by immunohistochemistry * Patients must have received prior systemic antineoplastic therapy * Patient is not amenable for curative therapy * Age \>= 18 years * Estimated life expectancy \> 3 months * Measurable disease on CT/MRI (at least one measurable lesion \>1cm) or chest X-ray (at least one measurable lesion \>2cm) * Karnofsky performance status of 60-100 * Adequate hematologic, renal and hepatic function * Subject is able to swallow and retain oral medication and does not have uncontrolled emesis * No fertility preserved * Written informed consent Exclusion Criteria: * Lack of or low expression of HDAC (see 4.1 "Pre-Screening") * Significant cardiac disease * Other invasive malignant tumor diagnosed within the last 5 years (e.g. metastases from breast cancer in the last 3 years) * Significant bowel obstruction * Severe uncontrolled infection * Known HIV-positivity * Symptomatic brain metastasis or leptomeningeal disease * Pre-existing significant liver disease, severe hepatic impairment (Bilirubin no greater than 1.5 times upper limit of normal (ULN) and/or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) greater than 2.5 times ULN) * Known history of allergic reaction to vorinostat …